Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Alvelestat · 2 trials · 4 indications
To evaluate the effect of alvelestat (MPH966) administered twice daily (bid) for 12 weeks on blood markers of within-individual % change in plasma desmosine/isodesmosine will be measured.
To evaluate the safety and tolerability of alvelestat (MPH966) administered twice daily (bid) for 12 weeks treatment numbers and % of subjects who experience at least 1 treatment-emergent adverse event (TEAE) will be measured.
| Arm | Type | Description |
|---|---|---|
| Alvelestat (MPH966) | ACTIVE_COMPARATOR | Alvelestat (MPH966) 120mg (4 30mg tablets) twice daily by mouth for 12 weeks |
| Placebo | PLACEBO_COMPARATOR | 4 Placebo tablets twice daily by mouth for 12 weeks |
| Placebo oral tablet | PLACEBO_COMPARATOR | placebo |
| Alvelestat oral tablet - dose 1 | ACTIVE_COMPARATOR | MPH966 |
| Alvelestat oral tablet - dose 2 | ACTIVE_COMPARATOR | MPH966 |
| Alvelestat oral tablet - dose 3 | ACTIVE_COMPARATOR | MPH966 |
| Name | Type | Description |
|---|---|---|
| Alvelestat (MPH966) | DRUG | Alvelestat was developed as treatment for lung diseases like Chronic Obstructive Pulmonary Disease. Alevelestat works by blocking certain proteins in the body that are responsible for inflammation and damage to the lungs that can lead to COPD symptoms. |
| Placebo | OTHER | Placebo is a pill or tablet that does not contain any study drug. |
| Alvelestat | DRUG | oral tablet |
Inclusion Criteria: Participants are eligible to be included in the study only if ALL of the following criteria apply: 1. Capable of giving signed informed consent as described in Appendix 3, which includes compliance with the requirements and restrictions listed in the informed consent form and i...
Alvelestat is an investigational small molecule being developed for Alpha-1 Antitrypsin Deficiency (AATD), a rare genetic condition, and for Covid-19. It has been studied in clinical trials for AATD-related COPD and emphysema, as well as for Covid-19.
Alvelestat is a small molecule that targets neutrophil elastase, an enzyme involved in tissue destruction in Alpha-1 Antitrypsin Deficiency. By inhibiting this enzyme, it aims to reduce lung damage associated with the condition.
Alvelestat is being developed by Mereo BioPharma Group plc, a biopharmaceutical company listed on the stock exchange under the ticker MREO. The company is focused on rare disease therapeutics.
Alvelestat is in Phase 2 clinical development. It has completed Phase 2 trials for Alpha-1 Antitrypsin Deficiency and a Phase 1 trial for Covid-19. It is not yet approved by the FDA and remains investigational.
Alvelestat has completed three clinical trials: NCT03636347, a Phase 2 study in AATD-related COPD; NCT03679598, a Phase 2 study in AATD; and NCT04539795, a Phase 1 study in Covid-19. All trials are completed.
Yes, Alvelestat is also known as MPH966. Clinical trial records reference both names, with MPH966 appearing in the titles of studies such as NCT03636347.